Qu Biologics Granted U.S. Patent for Use of E. coli to Treat Colon Cancer

VANCOUVER, BRITISH COLUMBIA--(Marketwired - May 20, 2014) - Qu Biologics Inc., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to "reboot" the body's immune system, announced it has been granted a U.S. patent covering the use of immunotherapies derived from components of E. coli to treat colon cancer.

Qu Biologics was issued U.S. Patent No. 8,501,198. The allowed claims relate to the use of E. coli components to stimulate an immune response to treat colon cancer. This latest patent follows Qu Biologics' first U.S. issued patent for the use of K. pneumoniae derived immunotherapies for the treatment of lung cancer.

Dr. Hal Gunn, Chief Executive Officer of Qu Biologics commented, "We are very pleased to have been granted another important cancer immunotherapy patent. Our SSIs aim to address the underlying immunological causes of chronic inflammatory diseases, representing a novel treatment approach that stimulates the body's own immune response to cancer. We will continue to further strengthen our patent position as we prepare for our first clinical trial in cancer to augment our current clinical trial in Crohn's disease."

Qu Biologics develops immunotherapies called Site Specific Immunomodulators (SSIs), which are derived from components of bacteria and are aimed at stimulating the body's immune system to treat cancer and immune-related disease. The company's SSI platform represents a promising new approach to the treatment of cancer and immune-related disease by addressing the immunological defect/deficiency that underlies these diseases. Qu Biologics has developed multiple SSIs, each of which targets a specific tissue/organ system.

About Qu Biologics

Qu Biologics develops Site Specific Immunomodulators (SSI), a novel class of immunotherapies that aim to reboot the body's immune system. SSIs are designed to stimulate an immune response in targeted organs or tissues to potentially reverse the chronic inflammation underlying many conditions including cancer and immune-related disease. The company is currently recruiting participants for a Phase 1/2 clinical trial to research SSI therapy for the treatment of Crohn's disease.

Backed by a prestigious group of scientific advisors and board members, Qu Biologics is led by a management team that includes co-founder and CEO Dr. Hal Gunn, a physician and expert on the body's immune response to chronic disease, Chief Medical Officer Dr. Simon Sutcliffe, former CEO of the BC Cancer Agency and a distinguished clinician, scientist and leader in cancer control internationally, and Chief Scientific Officer Dr. David Mullins, Assistant Professor of Microbiology and Immunology in the Norris Cotton Cancer Center at the Geisel School of Medicine at Dartmouth, and recognized expert in immune cell trafficking to tumours. For more information, visit www.qubiologics.com and www.qucrohnstrial.com.